Abstract c-Met is a receptor tyrosine kinase belonging to the MET (MNNG HOS transforming
gene) family, and is expressed on the surfaces of various cells. Hepatocyte growth factor …

Aberrant c‐Met activity has been implicated in the development of hepatocellular carcinoma
(HCC), suggesting that c‐Met inhibition may have therapeutic potential. However, clinical …

Summary Background Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved
overall survival and progression-free survival compared with placebo in a randomised …

Cancer is a major cause of death worldwide. MET tyrosine kinase receptor [MET, c-MET,
hepatocyte growth factor (HGF) receptor] pathway activation is associated with the …

Simple Summary Immunotherapies and molecularly targeted therapies have drastically
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …

MET and its ligand HGF are involved in many biological processes, both physiological and
pathological, making this signaling pathway an attractive therapeutic target in oncology …

Western and Eastern perspectives on therapeutic guidelines for hepatocellular carcinoma
(HCC) have many commonalities but may also differ in certain aspects, as described in this …

Hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) signaling
is involved in complex cellular programs that are important for embryonic development and …

Molecular characterization of oncogenic mutations within genes in the MAPK and
PI3K/AKT/mTOR pathways has led to the rational development of targeted therapies …

Hepatocellular carcinoma (HCC) is one of the most severe diseases worldwide. For the
different stages of HCC, there are different clinical treatment strategies, such as surgical …